<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04866381</url>
  </required_header>
  <id_info>
    <org_study_id>CIH-PQS-20210408</org_study_id>
    <nct_id>NCT04866381</nct_id>
  </id_info>
  <brief_title>An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody</brief_title>
  <official_title>An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to explore the efficacy of SHR-6390 and SHR-1020 in the&#xD;
      treatment of esophageal squamous cell carcinoma after progression on PD-1 Antibody.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>1 year</time_frame>
    <description>Objective Response Rate is defined as the percentage of patients whose tumors have a complete or partial response to treatment among eligible and treated patients. Objective response rate is defined consistent with Response Evaluation Criteria in Solid Tumors version 1.1 criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free-Survival</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Progression-Free-Survival is defined as time from treatment start date to date of progression or death from any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Overall survival is defined as time from treatment start date to date of death from any cause. Patients alive at the time of analysis are censored at last contact date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject safety</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">87</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <condition>Progression to PD-1 Antibody</condition>
  <arm_group>
    <arm_group_label>SHR-6390</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR-6390</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR-6390 combined with Camrelizumab (SHR-1210)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR-6390 combined with Camrelizumab (SHR-1210)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Camrelizumab (SHR-1210) combined with SHR-1020</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Camrelizumab (SHR-1210) combined with SHR-1020</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-6390</intervention_name>
    <description>SHR-6390</description>
    <arm_group_label>SHR-6390</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-6390 + Camrelizumab (SHR-1210)</intervention_name>
    <description>SHR-6390 combined with Camrelizumab (SHR-1210)</description>
    <arm_group_label>SHR-6390 combined with Camrelizumab (SHR-1210)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab (SHR-1210) + SHR-1020</intervention_name>
    <description>Camrelizumab (SHR-1210) combined with SHR-1020</description>
    <arm_group_label>Camrelizumab (SHR-1210) combined with SHR-1020</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who were diagnosed as esophageal squamous cell carcinoma by histopathology&#xD;
             with at least one measurable lesion according to RECIST 1.1 criteria.&#xD;
&#xD;
          -  Must have had progressive disease after previous treatment with PD-1 inhibitor&#xD;
&#xD;
          -  ECOG score 0-2&#xD;
&#xD;
          -  The expected survival time is ≥ 12 weeks&#xD;
&#xD;
          -  Previous permanent discontinuation did not occur due to adverse events associated with&#xD;
             immunotherapy, or the immunotreatment-related adverse events recovered to ≤1 grade&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Had other active malignant tumors within 5 years before entering the study&#xD;
&#xD;
          -  Had abnormal swallowing function or dysfunction of gastrointestinal absorption&#xD;
&#xD;
          -  The first study drug treatment was less than 28 days or 5 half-lives (in terms of&#xD;
             longer) from the last radiotherapy, chemotherapy, targeted therapy or immunotherapy&#xD;
&#xD;
          -  Patients who have already received surgery within 28 days (biopsy for diagnosis is&#xD;
             permitted)&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Qingsong Pang, MD</last_name>
      <phone>+86-22-23340123-1121</phone>
      <email>pangqingsong@tjmuch.com</email>
    </contact>
    <contact_backup>
      <last_name>Ting Deng, MD</last_name>
      <phone>+86-22-23340123-1051</phone>
      <email>xymcdengting@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 15, 2021</study_first_submitted>
  <study_first_submitted_qc>April 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2021</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

